{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:05:44Z","timestamp":1781247944759,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,22]]},"DOI":"10.7759\/cureus.86524","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T12:49:56Z","timestamp":1750596596000},"source":"Crossref","is-referenced-by-count":2,"title":["Comparison of Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) and Mitomycin C for the Treatment of Non-Muscle-Invasive Bladder Cancer"],"prefix":"10.7759","author":[{"given":"Kamran A","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Rafiuddin","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waqas Ahmed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Nisar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda Farwa","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Asif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review","volume":"324","author":"Lenis AT","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K. Bladder cancer: a review. JAMA. 2020, 324:1980-91. 10.1001\/jama.2020.17598","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-022-00578-1","article-title":"Recurrence mechanisms of non-muscle-invasive bladder cancer \u2014 a clinical perspective","volume":"19","author":"Teoh JY","year":"2022","unstructured":"Teoh JY, Kamat AM, Black PC, Grivas P, Shariat SF, Babjuk M. Recurrence mechanisms of non-muscle-invasive bladder cancer \u2014 a clinical perspective. Nat Rev Urol. 2022, 19:280-94. 10.1038\/s41585-022-00578-1","journal-title":"Nat Rev Urol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011935.pub2","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer","volume":"1","author":"Schmidt S","year":"2020","unstructured":"Schmidt S, Kunath F, Coles B, et al.. Intravesical Bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev. 2020, 1:CD011935. 10.1002\/14651858.CD011935.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15071937","article-title":"Efficacy of different bacillus of Calmette-Gu\u00e9rin (BCG) strains on recurrence rates among intermediate\/high-risk non-muscle invasive bladder cancers (NMIBCs): single-arm study systematic review, cumulative and network meta-analysis","volume":"15","author":"Del Giudice F","year":"2023","unstructured":"Del Giudice F, Asero V, Bologna E, et al.. Efficacy of different bacillus of Calmette-Gu\u00e9rin (BCG) strains on recurrence rates among intermediate\/high-risk non-muscle invasive bladder cancers (NMIBCs): single-arm study systematic review, cumulative and network meta-analysis. Cancers (Basel). 2023, 15:1937. 10.3390\/cancers15071937","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus Bacillus Calmette-Gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer","volume":"69","author":"Arends TJ","year":"2016","unstructured":"Arends TJ, Nativ O, Maffezzini M, et al.. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus Bacillus Calmette-Gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol. 2016, 69:1046-52. 10.1016\/j.eururo.2016.01.006","journal-title":"Eur Urol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2019180014","article-title":"Complications of intravesical BCG immunotherapy for bladder cancer","volume":"39","author":"Green DB","year":"2019","unstructured":"Green DB, Kawashima A, Menias CO, et al.. Complications of intravesical BCG immunotherapy for bladder cancer. Radiographics. 2019, 39:80-94. 10.1148\/rg.2019180014","journal-title":"Radiographics"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-021-03908-x","article-title":"Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage","volume":"40","author":"Balasubramanian A","year":"2022","unstructured":"Balasubramanian A, Gunjur A, Weickhardt A, Papa N, Bolton D, Lawrentschuk N, Perera M. Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage. World J Urol. 2022, 40:1111-24. 10.1007\/s00345-021-03908-x","journal-title":"World J Urol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.acuroe.2020.08.011","article-title":"Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC)","volume":"45","author":"\u00c1lvarez-Maestro M","year":"2021","unstructured":"\u00c1lvarez-Maestro M, Guerrero-Ramos F, Rodr\u00edguez-Faba O, Dom\u00ednguez-Escrig JL, Fern\u00e1ndez-G\u00f3mez JM. Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC). Actas Urol Esp (Engl Ed). 2021, 45:93-102. 10.1016\/j.acuroe.2020.08.011","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-015-6495-3","article-title":"Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer","volume":"99","author":"Begnini KR","year":"2015","unstructured":"Begnini KR, Buss JH, Collares T, Seixas FK. Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer. Appl Microbiol Biotechnol. 2015, 99:3741-54. 10.1007\/s00253-015-6495-3","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31020079","article-title":"BCG and alternative therapies to BCG therapy for non-muscle-invasive bladder cancer","volume":"31","author":"Lidagoster S","year":"2024","unstructured":"Lidagoster S, Ben-David R, De Leon B, Sfakianos JP. BCG and alternative therapies to BCG therapy for non-muscle-invasive bladder cancer. Curr Oncol. 2024, 31:1063-78. 10.3390\/curroncol31020079","journal-title":"Curr Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030694","article-title":"From interferon to checkpoint inhibition therapy\u2014a systematic review of new immune-modulating agents in Bacillus Calmette-Gu\u00e9rin (BCG) refractory non-muscle-invasive bladder cancer (NMIBC)","volume":"14","author":"Deininger S","year":"2022","unstructured":"Deininger S, T\u00f6rzs\u00f6k P, Mitterberger M, Pallauf M, Oswald D, Deininger C, Lusuardi L. From interferon to checkpoint inhibition therapy\u2014a systematic review of new immune-modulating agents in Bacillus Calmette-Gu\u00e9rin (BCG) refractory non-muscle-invasive bladder cancer (NMIBC). Cancers (Basel). 2022, 14:694. 10.3390\/cancers14030694","journal-title":"Cancers (Basel)"},{"key":"ref12","article-title":"The RCSI Sample Size Handbook: A Rough Guide","author":"Conroy RM","year":"2021","unstructured":"Conroy RM. The RCSI Sample Size Handbook: A Rough Guide. 2021."},{"key":"ref13","article-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","year":"2017","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. U.S. Department of Health and Human Services, 2017."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.02.063","article-title":"Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Gu\u00e9rin (BCG) in patients with non-muscle-invasive bladder carcinoma","volume":"52","author":"Friedrich MG","year":"2007","unstructured":"Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Gu\u00e9rin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol. 2007, 52:1123-29. 10.1016\/j.eururo.2007.02.063","journal-title":"Eur Urol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4103\/0970-1591.166475","article-title":"Treatment options in non-muscle-invasive bladder cancer after BCG failure","volume":"31","author":"Brooks NA","year":"2015","unstructured":"Brooks NA, O'Donnell MA. Treatment options in non-muscle-invasive bladder cancer after BCG failure. Indian J Urol. 2015, 31:312-9. 10.4103\/0970-1591.166475","journal-title":"Indian J Urol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.04.051","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder","volume":"54","author":"Babjuk M","year":"2008","unstructured":"Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, B\u00f6hle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008, 54:303-14. 10.1016\/j.eururo.2008.04.051","journal-title":"Eur Urol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang SS","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R, et al.. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol. 2016, 196:1021-9. 10.1016\/j.juro.2016.06.049","journal-title":"J Urol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/apm.13011","article-title":"Bacillus Calmette-Gu\u00e9rin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections","volume":"128","author":"Larsen ES","year":"2020","unstructured":"Larsen ES, Joensen UN, Poulsen AM, Goletti D, Johansen IS. Bacillus Calmette-Gu\u00e9rin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections. APMIS. 2020, 128:92-103. 10.1111\/apm.13011","journal-title":"APMIS"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3329\/bju.v24i1.59446","article-title":"Outcome of post-resection intravesical BCG and mitomycin C therapy on non-muscle invasive high-grade transitional cell carcinoma of urinary bladder","volume":"24","author":"Roy NC","year":"2021","unstructured":"Roy NC, Chowdhury MS, Karmaker U, Belal MT. Outcome of post-resection intravesical BCG and mitomycin C therapy on non-muscle invasive high-grade transitional cell carcinoma of urinary bladder. Bangladesh J Urol. 2021, 24:62-71. 10.3329\/bju.v24i1.59446","journal-title":"Bangladesh J Urol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.1196","article-title":"The management of BCG failure in non-muscle-invasive bladder cancer: an update","volume":"3","author":"Zlotta AR","year":"2009","unstructured":"Zlotta AR, Fleshner NE, Jewett MA. The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J. 2009, 3:S199-205. 10.5489\/cuaj.1196","journal-title":"Can Urol Assoc J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/375139-comparison-of-intravesical-bacillus-calmette-gurin-bcg-and-mitomycin-c-for-the-treatment-of-non-muscle-invasive-bladder-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T12:49:57Z","timestamp":1750596597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/375139-comparison-of-intravesical-bacillus-calmette-gurin-bcg-and-mitomycin-c-for-the-treatment-of-non-muscle-invasive-bladder-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,22]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.86524","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,22]]}}}